Stocktoria
HUTCHMED (China) Ltd HCM
HUTCHMED (China) Ltd (HCM) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $548.5M at a 83.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.27 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-23 | Goldman Sachs | Neutral (main) |
| 2026-07-07 | B of A Securities | Buy (main) |
| 2026-03-10 | B of A Securities | Buy (main) |
| 2025-09-22 | Morgan Stanley | Underweight (down) |
| 2025-07-22 | B of A Securities | Buy (main) |
| 2024-08-01 | Goldman Sachs | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.714 |
| Retained earnings / assets | -0.216 |
| EBIT / assets | -0.022 |
| Equity / liabilities | 2.493 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| MIRM | Mirum Pharmaceuticals, Inc. | 4/9 | 0.54 | — | +54.7% |
| CPRX | CATALYST PHARMACEUTICALS, INC. | 4/9 | 14.1 | 18 | +19.8% |
| BBIO | BridgeBio Pharma, Inc. | 1/9 | -14.22 | — | +126.3% |
| TVTX | Travere Therapeutics, Inc. | 5/9 | -5.38 | — | +110.5% |
| INSM | INSMED Inc | 3/9 | -7.47 | — | +66.7% |
About HUTCHMED (China) Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
FAQ
Is HCM financially healthy?
HUTCHMED (China) Ltd's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does HCM pay a dividend?
No, HUTCHMED (China) Ltd does not currently pay a dividend.
How profitable is HCM?
In FY2025, HUTCHMED (China) Ltd had a net margin of 83.3% and a return on equity of 36.5%.
Is HCM overvalued or undervalued?
HUTCHMED (China) Ltd trades at about 23.6× trailing earnings — below its 10-year norm (10-year range 28.8×–704.5×, median 338.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for HCM?
The average Wall-Street price target for HUTCHMED (China) Ltd is $21.49, about 75.4% above the recent price, from 14 analysts (consensus: buy).
Is HCM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HUTCHMED (China) Ltd: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 31.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.